In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medik.
OBJECTIVE
To assess the anti-hepatitis B virus (HBV) effect of hyperoside extracted from Abelmoschus manihot (L) medik.


METHODS
The human hepatoma Hep G2.2.15 cell culture system and duck hepatitis B virus (DHBV) infection model were used as in vivo and in vitro models to evaluate the anti-HBV effects.


RESULTS
In the cell model, the 50% toxic concentration of hyperoside was 0.115 g/L; the maximum nontoxic concentration was 0.05 g/L. On the maximum nontoxic concentrations, the inhibition rates of hyperoside on HBeAg and HBsAg in the 2.2.15 cells were 86.41% and 82.27% on d 8, respectively. In the DHBV infection model, the DHBV-DNA levels decreased significantly in the treatment of 0.05 g x kg(-1 ) x d(-1 ) and 0.10 g x kg(-1) x d(-1) dosage groups of hyperoside (P<0.01). The inhibition of the peak of viremia was at the maximum at the dose of 0.10 g x kg(-1 ) x d(-1) and reached 60.79% on d 10 and 69.78% on d 13, respectively.


CONCLUSIONS
These results suggested that hyperoside is a strong inhibitor of HBsAg and HBeAg secretion in 2.2.15 cells and DHBV-DNA levels in the HBV-infected duck model.
Wu
Lin-Lin
LL
Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China.
Yang
Xin-Bo
XB
Huang
Zheng-Ming
ZM
Liu
He-Zhi
HZ
Wu
Guang-Xia
GX
D028483:Abelmoschus / Q000737:chemistry*; D000818:Animals; D000998:Antiviral Agents / Q000302:isolation & purification / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004279:DNA, Viral / Q000096:biosynthesis / Q000235:genetics; D004372:Ducks; D006509:Hepatitis B / Q000188:drug therapy / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000032:analysis / Q000096:biosynthesis; D006513:Hepatitis B e Antigens / Q000032:analysis / Q000096:biosynthesis; D006515:Hepatitis B virus / Q000187:drug effects; D006801:Humans; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology; D011794:Quercetin / Q000031:analogs & derivatives* / Q000302:isolation & purification / Q000494:pharmacology
D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D010936:Plant Extracts; C021304:hyperoside; D011794:Quercetin